Brief: Vetbiolix Announces Starts Study To Confirm Clinical Benefit With Vbx-1000
12/02/2026 07:36
Feb 12 (Reuters) - Medivir AB MEDIVIR.ST: MEDIVIR: MEDIVIR’S PARTNER VETBIOLIX ANNOUNCES INITIATION OF RANDOMIZED, PLACEBO-CONTROLLED STUDY TO CONFIRM CLINICAL BENEFIT WITH VBX-1000 (MIV-701) TOP-LINE DATA EXPECTED BY Q4 2026 Source text: ID:nMFN9dSmFN Further company coverage: MEDIVIR.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))